top of page

Cardiovascular

Health

CardioMetabolic 

Health

Lung Health

Bone Health

All-in-one AI-CVD

497e6f54-782b-4e077a-3a7144e4f3e4.png

AutoFracture

(coming soon)

upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
0bdba309-a76a-4215-b207-90a7932bb681.png
iScreen Shoter - 20260520111737117 1.png
Frame 1000004271.png
iScreen Shoter - 20260520105243724 1.png
iScreen Shoter - 20260520105243724 1.png
iScreen Shoter - 20260520100645073 1.png

1 Non-Contrast Scan              10+ Actionable Reports

​About

About

Heart Disease Prevention Program, Mary and Steve Wen Cardiovascular Division, University of California Irvine School of Medicine, CA 92697, USA

Purpose:
To evaluate the predictive value of myosteatosis as an opportunistic finding in coronary artery calcium (CAC) CT scans for clinically diagnosed chronic obstructive pulmonary disease (COPD) and compare it with an artificial intelligence (AI)–measured biomarker of emphysema derived from the same scans.


Materials and Methods:
In this prospective study, baseline CAC CT scans and 20-year follow-up data were analyzed. Myosteatosis was defined as the lowest quartile of thoracic skeletal muscle mean attenuation (males < 33.5 HU, females < 27.0 HU). The emphysema-like lung biomarker was quantified as the percentage of lung voxels below −950 HU in CAC CT scans. COPD was identified using the International Classification of Diseases, Ninth Revision, Clinical Modification, and International Classification of Diseases, 10th Revision, Clinical Modification diagnostic codes from hospital discharge records. Hazard ratios (HRs) for COPD were calculated using proportional hazard regression models, comparing the bottom versus top quartiles of myosteatosis and emphysema-like lung measurements.


Results:
Among 5,535 participants in the Multi-Ethnic Study of Atherosclerosis (mean age ± SD, 62.2 years ± 10.3, 47.6% males), 396 (7.1%) were diagnosed with COPD over the 20-year follow-up period. Myosteatosis showed a stronger association with COPD than emphysema (unadjusted HRs, 5.98 [95% CI: 4.14, 8.63] and 2.12 [95% CI: 1.61, 2.78], respectively [P < .001]). After adjusting for covariates (age, sex, smoking status, body mass index, race, asthma, physical activity, inflammatory markers, and insulin resistance),

Latest Publications

Collabrators

Ali Hashemi

Heart Disease Prevention Program, Mary and Steve Wen Cardiovascular Division, University of California Irvine School of Medicine, CA 92697, USA

Anthony Reeves PhD.

Heart Disease Prevention Program, Mary and Steve Wen Cardiovascular Division, University of California Irvine School of Medicine, CA 92697, USA

Amir Azimi MD.

Heart Disease Prevention Program, Mary and Steve Wen Cardiovascular Division, University of California Irvine School of Medicine, CA 92697, USA

Kyle Atlas

Heart Disease Prevention Program, Mary and Steve Wen Cardiovascular Division, University of California Irvine School of Medicine, CA 92697, USA

Jakob Wasserthal

Heart Disease Prevention Program, Mary and Steve Wen Cardiovascular Division, University of California Irvine School of Medicine, CA 92697, USA

Seyed Reza Mirjalili MD.

Heart Disease Prevention Program, Mary and Steve Wen Cardiovascular Division, University of California Irvine School of Medicine, CA 92697, USA

Chenyu Zhang

Heart Disease Prevention Program, Mary and Steve Wen Cardiovascular Division, University of California Irvine School of Medicine, CA 92697, USA

Conference Presentations

Ready to Unlock the Value in Your CT Scans?

Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Youtube

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

aicvd patent_edited_edited.jpg
ISO LOGO_edited.png

©2026 HeartLung Corporation. All Rights Reserved. US Patent Nos US9119590*, US10695022, US11610686, US18167691, US20240115224, and Patents Pending. AI-CVD, AI-CAC, AutoBMD, AutoCAC, AutoChamber and other trademarks shown on this website are protected under intellectual property rights of HeartLung Corporation in the United States.

bottom of page